S&P 500   3,974.99 (+0.97%)
DOW   32,258.22 (+0.71%)
QQQ   312.18 (+1.98%)
AAPL   160.32 (+1.58%)
MSFT   279.85 (+2.78%)
META   206.01 (+3.10%)
GOOGL   105.93 (+2.48%)
AMZN   100.03 (+1.35%)
TSLA   194.96 (+1.99%)
NVDA   273.26 (+3.24%)
NIO   9.31 (+2.42%)
BABA   86.63 (+3.56%)
AMD   101.41 (+3.92%)
T   18.52 (+0.71%)
F   11.60 (+1.05%)
MU   61.18 (+5.17%)
CGC   1.91 (+1.33%)
GE   91.88 (+2.56%)
DIS   96.63 (+1.82%)
AMC   4.53 (+4.38%)
PFE   40.47 (+1.15%)
PYPL   73.38 (-1.29%)
NFLX   320.27 (+8.97%)
S&P 500   3,974.99 (+0.97%)
DOW   32,258.22 (+0.71%)
QQQ   312.18 (+1.98%)
AAPL   160.32 (+1.58%)
MSFT   279.85 (+2.78%)
META   206.01 (+3.10%)
GOOGL   105.93 (+2.48%)
AMZN   100.03 (+1.35%)
TSLA   194.96 (+1.99%)
NVDA   273.26 (+3.24%)
NIO   9.31 (+2.42%)
BABA   86.63 (+3.56%)
AMD   101.41 (+3.92%)
T   18.52 (+0.71%)
F   11.60 (+1.05%)
MU   61.18 (+5.17%)
CGC   1.91 (+1.33%)
GE   91.88 (+2.56%)
DIS   96.63 (+1.82%)
AMC   4.53 (+4.38%)
PFE   40.47 (+1.15%)
PYPL   73.38 (-1.29%)
NFLX   320.27 (+8.97%)
S&P 500   3,974.99 (+0.97%)
DOW   32,258.22 (+0.71%)
QQQ   312.18 (+1.98%)
AAPL   160.32 (+1.58%)
MSFT   279.85 (+2.78%)
META   206.01 (+3.10%)
GOOGL   105.93 (+2.48%)
AMZN   100.03 (+1.35%)
TSLA   194.96 (+1.99%)
NVDA   273.26 (+3.24%)
NIO   9.31 (+2.42%)
BABA   86.63 (+3.56%)
AMD   101.41 (+3.92%)
T   18.52 (+0.71%)
F   11.60 (+1.05%)
MU   61.18 (+5.17%)
CGC   1.91 (+1.33%)
GE   91.88 (+2.56%)
DIS   96.63 (+1.82%)
AMC   4.53 (+4.38%)
PFE   40.47 (+1.15%)
PYPL   73.38 (-1.29%)
NFLX   320.27 (+8.97%)
S&P 500   3,974.99 (+0.97%)
DOW   32,258.22 (+0.71%)
QQQ   312.18 (+1.98%)
AAPL   160.32 (+1.58%)
MSFT   279.85 (+2.78%)
META   206.01 (+3.10%)
GOOGL   105.93 (+2.48%)
AMZN   100.03 (+1.35%)
TSLA   194.96 (+1.99%)
NVDA   273.26 (+3.24%)
NIO   9.31 (+2.42%)
BABA   86.63 (+3.56%)
AMD   101.41 (+3.92%)
T   18.52 (+0.71%)
F   11.60 (+1.05%)
MU   61.18 (+5.17%)
CGC   1.91 (+1.33%)
GE   91.88 (+2.56%)
DIS   96.63 (+1.82%)
AMC   4.53 (+4.38%)
PFE   40.47 (+1.15%)
PYPL   73.38 (-1.29%)
NFLX   320.27 (+8.97%)
NYSE:TARO

Taro Pharmaceutical Industries - TARO Stock Forecast, Price & News

$25.03
+0.03 (+0.12%)
(As of 03/23/2023 12:04 PM ET)
Add
Compare
Today's Range
$25.00
$25.32
50-Day Range
$25.00
$31.59
52-Week Range
$24.98
$45.62
Volume
3,507 shs
Average Volume
12,198 shs
Market Capitalization
$940.63 million
P/E Ratio
20.52
Dividend Yield
N/A
Price Target
$35.00

Taro Pharmaceutical Industries MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
40.0% Upside
$35.00 Price Target
Short Interest
Bearish
0.72% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.56mentions of Taro Pharmaceutical Industries in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

386th out of 986 stocks

Pharmaceutical Preparations Industry

176th out of 477 stocks


TARO stock logo

About Taro Pharmaceutical Industries (NYSE:TARO) Stock

Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada and Israel. Its products include semi-solids formulations, such as creams and ointments and other dosage forms such as liquids, capsules and tablets, in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. The company was founded in 1950 and is headquartered in Haifa Bay, Israel.

Receive TARO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taro Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

TARO Stock News Headlines

Topical Drug Delivery Global Market Report 2023
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
TARO Taro Pharmaceutical Industries Ltd.
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
See More Headlines
Receive TARO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taro Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

TARO Company Calendar

Last Earnings
1/24/2023
Today
3/23/2023
Fiscal Year End
3/31/2023
Next Earnings (Estimated)
5/25/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
1,455
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$35.00
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
+40.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$58.27 million
Pretax Margin
7.96%

Debt

Sales & Book Value

Annual Sales
$569.41 million
Cash Flow
$3.90 per share
Book Value
$45.54 per share

Miscellaneous

Free Float
32,398,000
Market Cap
$939.63 million
Optionable
Optionable
Beta
0.66

Key Executives

  • Uday Vijaykumar Baldota
    Chief Executive Officer & Director
  • William J. Coote
    Chief Financial, VP & Accounting Officer
  • Hagai Reingold
    Vice President & Head-Operations
  • Itamar Karsenti
    Vice President & Head-Operations
  • Avi Avramoff
    Vice President & Head-Research & Development













TARO Stock - Frequently Asked Questions

Should I buy or sell Taro Pharmaceutical Industries stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" TARO shares.
View TARO analyst ratings
or view top-rated stocks.

What is Taro Pharmaceutical Industries' stock price forecast for 2023?

1 equities research analysts have issued 1 year price objectives for Taro Pharmaceutical Industries' shares. Their TARO share price forecasts range from $35.00 to $35.00. On average, they anticipate the company's stock price to reach $35.00 in the next twelve months. This suggests a possible upside of 40.0% from the stock's current price.
View analysts price targets for TARO
or view top-rated stocks among Wall Street analysts.

How have TARO shares performed in 2023?

Taro Pharmaceutical Industries' stock was trading at $29.04 on January 1st, 2023. Since then, TARO shares have decreased by 13.9% and is now trading at $25.00.
View the best growth stocks for 2023 here
.

When is Taro Pharmaceutical Industries' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 25th 2023.
View our TARO earnings forecast
.

How were Taro Pharmaceutical Industries' earnings last quarter?

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) issued its earnings results on Tuesday, January, 24th. The company reported $0.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.87 by $0.68. The firm earned $139.20 million during the quarter, compared to analysts' expectations of $163.12 million. Taro Pharmaceutical Industries had a net margin of 8.06% and a trailing twelve-month return on equity of 2.68%.

What ETFs hold Taro Pharmaceutical Industries' stock?

ETFs with the largest weight of Taro Pharmaceutical Industries (NYSE:TARO) stock in their portfolio include ARK Israel Innovative Technology ETF (IZRL) and iShares MSCI Israel ETF (EIS).VanEck Israel ETF (ISRA).

What is Uday Baldota's approval rating as Taro Pharmaceutical Industries' CEO?

11 employees have rated Taro Pharmaceutical Industries Chief Executive Officer Uday Baldota on Glassdoor.com. Uday Baldota has an approval rating of 19% among the company's employees. This puts Uday Baldota in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Taro Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Broadcom (AVGO), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Skyworks Solutions (SWKS), GW Pharmaceuticals (GWPH), Delta Air Lines (DAL), Jazz Pharmaceuticals (JAZZ) and Southwest Airlines (LUV).

What is Taro Pharmaceutical Industries' stock symbol?

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

Who are Taro Pharmaceutical Industries' major shareholders?

Taro Pharmaceutical Industries' stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.63%), Dimensional Fund Advisors LP (1.52%), Eversept Partners LP (0.60%), Murchinson Ltd. (0.28%), Cowen AND Company LLC (0.19%) and ARK Investment Management LLC (0.18%).

How do I buy shares of Taro Pharmaceutical Industries?

Shares of TARO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Taro Pharmaceutical Industries' stock price today?

One share of TARO stock can currently be purchased for approximately $25.00.

How much money does Taro Pharmaceutical Industries make?

Taro Pharmaceutical Industries (NYSE:TARO) has a market capitalization of $939.63 million and generates $569.41 million in revenue each year. The company earns $58.27 million in net income (profit) each year or $1.22 on an earnings per share basis.

How many employees does Taro Pharmaceutical Industries have?

The company employs 1,455 workers across the globe.

How can I contact Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries' mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The official website for the company is www.taro.com. The company can be reached via phone at (724) 847-5700, via email at investorrelations@taro.com, or via fax at 914-345-6169.

This page (NYSE:TARO) was last updated on 3/23/2023 by MarketBeat.com Staff